Drugs / PF-06647263
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02078752 | Apr 2014 → May 2017 | triple-negative breast carcinoma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06647263 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02078752 ↗ |
| Route | Intravenous | “PF-06647263 will be administered intravenously” NCT02078752 ↗ |
| Target | EFNA4 | “PF-06647263, a novel antibody-drug conjugate consisting of an anti-EFNA4 antibody linked to a calicheamicin payload” PMID 30680712 ↗ Feb 2019 |